-
1
-
-
59149084542
-
Targeted proteomic strategy for clinical biomarker discovery
-
Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol. 2009;3(1):33-44.
-
(2009)
Mol Oncol.
, vol.3
, Issue.1
, pp. 33-44
-
-
Schiess, R.1
Wollscheid, B.2
Aebersold, R.3
-
2
-
-
14344251403
-
New science-based endpoints to accelerate oncology drug development
-
Kelloff GJ, Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer. 2005;41(4):491-501.
-
(2005)
Eur J Cancer.
, vol.41
, Issue.4
, pp. 491-501
-
-
Kelloff, G.J.1
Sigman, C.C.2
-
3
-
-
84863168143
-
Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures
-
Lussier YA, Stadler WM, Chen JL. Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc. 2012;19(2):156-60.
-
(2012)
J Am Med Inform Assoc.
, vol.19
, Issue.2
, pp. 156-160
-
-
Lussier, Y.A.1
Stadler, W.M.2
Chen, J.L.3
-
4
-
-
84999605219
-
-
eukemia
-
Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, et al. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014.
-
(2014)
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma
-
-
Amin, S.B.1
Yip, W.K.2
Minvielle, S.3
Broyl, A.4
Li, Y.5
Hanlon, B.6
-
5
-
-
84872967522
-
Cancer statistics, 2013
-
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
-
(2013)
CA Cancer J Clin.
, vol.63
, Issue.1
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
6
-
-
33846436108
-
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program
-
Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20-37.
-
(2007)
Oncologist.
, vol.12
, Issue.1
, pp. 20-37
-
-
Hayat, M.J.1
Howlader, N.2
Reichman, M.E.3
Edwards, B.K.4
-
7
-
-
84892699941
-
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
-
Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
-
(2014)
Nat Commun
, vol.5
, pp. 2997
-
-
Bolli, N.1
Avet-Loiseau, H.2
Wedge, D.C.3
Van Loo, P.4
Alexandrov, L.B.5
Martincorena, I.6
-
8
-
-
84879144365
-
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach
-
Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013;121(16):3147-52.
-
(2013)
Blood.
, vol.121
, Issue.16
, pp. 3147-3152
-
-
Baker, A.1
Braggio, E.2
Jacobus, S.3
Jung, S.4
Larson, D.5
Therneau, T.6
-
9
-
-
79952940092
-
Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma
-
Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP, Jr., et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010;10(6):464-8.
-
(2010)
Clin Lymphoma Myeloma Leuk.
, vol.10
, Issue.6
, pp. 464-468
-
-
Talamo, G.1
Farooq, U.2
Zangari, M.3
Liao, J.4
Dolloff, N.G.5
Loughran Jr., T.P.6
-
10
-
-
82555205476
-
The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma
-
Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011;17(23):7402-12.
-
(2011)
Clin Cancer Res.
, vol.17
, Issue.23
, pp. 7402-7412
-
-
Agnelli, L.1
Forcato, M.2
Ferrari, F.3
Tuana, G.4
Todoerti, K.5
Walker, B.A.6
-
12
-
-
79955650000
-
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma
-
Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer genetics. 2011;204(1):3-12.
-
(2011)
Cancer genetics.
, vol.204
, Issue.1
, pp. 3-12
-
-
Sawyer, J.R.1
-
13
-
-
0036322185
-
Current therapy for multiple myeloma
-
Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77(8):813-22.
-
(2002)
Mayo Clin Proc.
, vol.77
, Issue.8
, pp. 813-822
-
-
Rajkumar, S.V.1
Gertz, M.A.2
Kyle, R.A.3
Greipp, P.R.4
-
14
-
-
84920898199
-
Second transplants for multiple myeloma relapsing after a previous autotransplant- reduced-intensity allogeneic vs autologous transplantation
-
Freytes CO, Vesole DH, Lerademacher J, Zhong X, Gale RP, Kyle RA, et al. Second transplants for multiple myeloma relapsing after a previous autotransplant- reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2013.
-
(2013)
Bone Marrow Transplant
-
-
Freytes, C.O.1
Vesole, D.H.2
Lerademacher, J.3
Zhong, X.4
Gale, R.P.5
Kyle, R.A.6
-
15
-
-
80053111637
-
Approach to the treatment of multiple myeloma: a clash of philosophies
-
Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011;118(12):3205-11.
-
(2011)
Blood.
, vol.118
, Issue.12
, pp. 3205-3211
-
-
Rajkumar, S.V.1
Gahrton, G.2
Bergsagel, P.L.3
-
16
-
-
84882722657
-
Current and Emerging Treatment Options for Patients with Relapsed Myeloma
-
Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, Cugno M. Current and Emerging Treatment Options for Patients with Relapsed Myeloma. Clin Med Insights Oncol. 2013;7:209-19.
-
(2013)
Clin Med Insights Oncol
, vol.7
, pp. 209-219
-
-
Castelli, R.1
Gualtierotti, R.2
Orofino, N.3
Losurdo, A.4
Gandolfi, S.5
Cugno, M.6
-
17
-
-
14544303662
-
Proteasome inhibition as a novel therapeutic target in human cancer
-
Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630-9.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.3
, pp. 630-639
-
-
Rajkumar, S.V.1
Richardson, P.G.2
Hideshima, T.3
Anderson, K.C.4
-
18
-
-
84857913363
-
Latest advances and current challenges in the treatment of multiple myeloma
-
Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135-43.
-
(2012)
Nat Rev Clin Oncol.
, vol.9
, Issue.3
, pp. 135-143
-
-
Mahindra, A.1
Laubach, J.2
Raje, N.3
Munshi, N.4
Richardson, P.G.5
Anderson, K.6
-
19
-
-
84867295563
-
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
-
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-25.
-
(2012)
Blood.
, vol.120
, Issue.14
, pp. 2817-2825
-
-
Siegel, D.S.1
Martin, T.2
Wang, M.3
Vij, R.4
Jakubowiak, A.J.5
Lonial, S.6
-
20
-
-
79955461011
-
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
-
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-40.
-
(2011)
Lancet Oncol.
, vol.12
, Issue.5
, pp. 431-440
-
-
Moreau, P.1
Pylypenko, H.2
Grosicki, S.3
Karamanesht, I.4
Leleu, X.5
Grishunina, M.6
-
21
-
-
84860709392
-
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
-
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
-
(2012)
N Engl J Med.
, vol.366
, Issue.19
, pp. 1782-1791
-
-
Attal, M.1
Lauwers-Cances, V.2
Marit, G.3
Caillot, D.4
Moreau, P.5
Facon, T.6
-
22
-
-
84860741191
-
Lenalidomide after stem-cell transplantation for multiple myeloma
-
McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
-
(2012)
N Engl J Med.
, vol.366
, Issue.19
, pp. 1770-1781
-
-
McCarthy, P.L.1
Owzar, K.2
Hofmeister, C.C.3
Hurd, D.D.4
Hassoun, H.5
Richardson, P.G.6
-
23
-
-
84905294644
-
Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma
-
Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One. 2013;8(10):e77608.
-
(2013)
PLoS One.
, vol.8
, Issue.10
-
-
Stessman, H.A.1
Mansoor, A.2
Zhan, F.3
Linden, M.A.4
Van Ness, B.5
Baughn, L.B.6
-
24
-
-
61849152933
-
Many facets of bortezomib resistance/susceptibility
-
Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. Blood. 2008;112(6):2177-8.
-
(2008)
Blood.
, vol.112
, Issue.6
, pp. 2177-2178
-
-
Kumar, S.1
Rajkumar, S.V.2
-
25
-
-
84864568543
-
Proteasome inhibitors in multiple myeloma: 10 years later
-
Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-59.
-
(2012)
Blood.
, vol.120
, Issue.5
, pp. 947-959
-
-
Moreau, P.1
Richardson, P.G.2
Cavo, M.3
Orlowski, R.Z.4
San Miguel, J.F.5
Palumbo, A.6
-
26
-
-
79953125606
-
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
-
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266-83.
-
(2011)
Cancer Treat Rev.
, vol.37
, Issue.4
, pp. 266-283
-
-
van de Donk, N.W.1
Lokhorst, H.M.2
Dimopoulos, M.3
Cavo, M.4
Morgan, G.5
Einsele, H.6
-
27
-
-
84904054234
-
-
Leukemia
-
Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, et al. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 2014.
-
(2014)
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
-
-
Berenson, J.R.1
Hilger, J.D.2
Yellin, O.3
Dichmann, R.4
Patel-Donnelly, D.5
Boccia, R.V.6
-
28
-
-
49649083607
-
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma
-
Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma. 2008;8(3):140-5.
-
(2008)
Clin Lymphoma Myeloma.
, vol.8
, Issue.3
, pp. 140-145
-
-
Conner, T.M.1
Doan, Q.D.2
Walters, I.B.3
LeBlanc, A.L.4
Beveridge, R.A.5
-
29
-
-
80053356808
-
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
-
Shaughnessy JD, Jr., Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011;118(13):3512-24.
-
(2011)
Blood.
, vol.118
, Issue.13
, pp. 3512-3524
-
-
Shaughnessy Jr., J.D.1
Qu, P.2
Usmani, S.3
Heuck, C.J.4
Zhang, Q.5
Zhou, Y.6
-
30
-
-
84879293601
-
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model
-
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013;12(6):1140-50.
-
(2013)
Mol Cancer Ther.
, vol.12
, Issue.6
, pp. 1140-1150
-
-
Stessman, H.A.1
Baughn, L.B.2
Sarver, A.3
Xia, T.4
Deshpande, R.5
Mansoor, A.6
-
31
-
-
79953814654
-
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
-
Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011;117(14):3847-57.
-
(2011)
Blood.
, vol.117
, Issue.14
, pp. 3847-3857
-
-
Zhu, Y.X.1
Tiedemann, R.2
Shi, C.X.3
Yin, H.4
Schmidt, J.E.5
Bruins, L.A.6
-
32
-
-
84901465114
-
Translating a gene expression signature for multiple Myeloma prognosis into a robust high-throughput assay for clinical use
-
van Laar R FR, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr. Translating a gene expression signature for multiple Myeloma prognosis into a robust high-throughput assay for clinical use. BMC Medical Genomics 2014.
-
(2014)
BMC Medical Genomics
-
-
van Laar, R.F.R.1
Brown, N.2
Ramsey, J.3
Riccitelli, S.4
Heuck, C.5
Barlogie, B.6
Shaughnessy Jr., J.D.7
-
33
-
-
77955712506
-
Bortezomib- resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
-
Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, et al. Bortezomib- resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010;24(8):1506-12.
-
(2010)
Leukemia.
, vol.24
, Issue.8
, pp. 1506-1512
-
-
Ri, M.1
Iida, S.2
Nakashima, T.3
Miyazaki, H.4
Mori, F.5
Ito, A.6
-
34
-
-
84870483290
-
Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
-
Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi HL, et al. Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012;120(23):4513-6.
-
(2012)
Blood.
, vol.120
, Issue.23
, pp. 4513-4516
-
-
Lichter, D.I.1
Danaee, H.2
Pickard, M.D.3
Tayber, O.4
Sintchak, M.5
Shi, H.L.6
-
35
-
-
84883625365
-
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma
-
Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer cell. 2013;24(3):289-304.
-
(2013)
Cancer cell.
, vol.24
, Issue.3
, pp. 289-304
-
-
Leung-Hagesteijn, C.1
Erdmann, N.2
Cheung, G.3
Keats, J.J.4
Stewart, A.K.5
Reece, D.E.6
-
36
-
-
84885595409
-
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib
-
Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013;27(10):2075-7.
-
(2013)
Leukemia.
, vol.27
, Issue.10
, pp. 2075-2077
-
-
Stessman, H.A.1
Mansoor, A.2
Zhan, F.3
Janz, S.4
Linden, M.A.5
Baughn, L.B.6
-
37
-
-
84877029737
-
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib
-
Fernandez de Larrea C, Martin-Antonio B, Cibeira MT, Navarro A, Tovar N, Diaz T, et al. Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leuk Res. 2013;37(6):641-6.
-
(2013)
Leuk Res.
, vol.37
, Issue.6
, pp. 641-646
-
-
Fernandez de Larrea, C.1
Martin-Antonio, B.2
Cibeira, M.T.3
Navarro, A.4
Tovar, N.5
Diaz, T.6
-
38
-
-
84884494098
-
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
-
Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013;122(2):219-26.
-
(2013)
Blood.
, vol.122
, Issue.2
, pp. 219-226
-
-
Kaiser, M.F.1
Johnson, D.C.2
Wu, P.3
Walker, B.A.4
Brioli, A.5
Mirabella, F.6
-
39
-
-
84892409192
-
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
-
Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
-
(2014)
Cancer Cell.
, vol.25
, Issue.1
, pp. 91-101
-
-
Lohr, J.G.1
Stojanov, P.2
Carter, S.L.3
Cruz-Gordillo, P.4
Lawrence, M.S.5
Auclair, D.6
-
40
-
-
84905690692
-
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
-
Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28(8):1705-15.
-
(2014)
Leukemia.
, vol.28
, Issue.8
, pp. 1705-1715
-
-
Melchor, L.1
Brioli, A.2
Wardell, C.P.3
Murison, A.4
Potter, N.E.5
Kaiser, M.F.6
-
41
-
-
84868156832
-
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
-
Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120(16):3260-70.
-
(2012)
Blood.
, vol.120
, Issue.16
, pp. 3260-3270
-
-
Kuhn, D.J.1
Berkova, Z.2
Jones, R.J.3
Woessner, R.4
Bjorklund, C.C.5
Ma, W.6
-
42
-
-
84884699420
-
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
-
Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331-7.
-
(2013)
Blood.
, vol.122
, Issue.14
, pp. 2331-2337
-
-
Richardson, P.G.1
Schlossman, R.L.2
Alsina, M.3
Weber, D.M.4
Coutre, S.E.5
Gasparetto, C.6
-
43
-
-
84862878624
-
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
-
Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53(9):1820-3.
-
(2012)
Leuk Lymphoma.
, vol.53
, Issue.9
, pp. 1820-1823
-
-
Wolf, J.L.1
Siegel, D.2
Goldschmidt, H.3
Hazell, K.4
Bourquelot, P.M.5
Bengoudifa, B.R.6
-
44
-
-
84920934165
-
Composite patient reports: a laboratory informatics perspective and pilot project for personalized medicine and translational research
-
Gundlapalli AV, Delgado JC, Jackson BR, Tricot GJ, Hill HR. Composite patient reports: a laboratory informatics perspective and pilot project for personalized medicine and translational research. Summit on Translat Bioinforma. 2009;2009:39-43.
-
(2009)
Summit on Translat Bioinforma
, vol.2009
, pp. 39-43
-
-
Gundlapalli, A.V.1
Delgado, J.C.2
Jackson, B.R.3
Tricot, G.J.4
Hill, H.R.5
|